Skip to Main Content
Table 1—

Studies included in the integrated analysis

Study (ref. no.)Number of randomized and treated patientsStudy durationPrestudy treatmentStudy treatmentAdditional antidiabetic treatment
3002 (8,14) 570 52 weeks* OAD and once-daily insulin or OAD alone Once daily at bedtime: insulin glargine or NPH insulin OAD(s) 
3006 (12,15) 518 28 weeks Insulin for >3 months (no OAD) Insulin glargine once daily at bedtime or NPH once or twice daily Regular human insulin 
4001 (16) 460 28 weeks OAD for >6 months Once daily at bedtime: insulin glargine or NPH insulin OAD (glimepiride) 
4002 (13) 756 24 weeks OAD alone Once daily at bedtime: insulin glargine or NPH insulin OAD(s) 
Study (ref. no.)Number of randomized and treated patientsStudy durationPrestudy treatmentStudy treatmentAdditional antidiabetic treatment
3002 (8,14) 570 52 weeks* OAD and once-daily insulin or OAD alone Once daily at bedtime: insulin glargine or NPH insulin OAD(s) 
3006 (12,15) 518 28 weeks Insulin for >3 months (no OAD) Insulin glargine once daily at bedtime or NPH once or twice daily Regular human insulin 
4001 (16) 460 28 weeks OAD for >6 months Once daily at bedtime: insulin glargine or NPH insulin OAD (glimepiride) 
4002 (13) 756 24 weeks OAD alone Once daily at bedtime: insulin glargine or NPH insulin OAD(s) 
*

The 20-week data used for the original study were included in this analysis.

In this study, insulin glargine was given once daily at breakfast or bedtime. Only those receiving insulin glargine at bedtime are included in this analysis. OAD, oral antidiabetic drug.

Close Modal

or Create an Account

Close Modal
Close Modal